Harmonic Discovery is a resident of JLABS NYC, part of Johnson & Johnson Innovation's global network of life science incubators. With this new funding, Harmonic Discovery plans to advance its drug discovery platform and pipeline by expanding its leadership team, building proprietary chemical libraries, and scaling its laboratory operations.
Dudley was previously the Chief Scientific Officer at Tempus and Associate Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. Their machine learning models and computational approaches are extremely precise and have been validated experimentally," said Joel Dudley, PhD and Partner at Innovation Endeavors. The strength of their computational platform and methodology is a breakthrough in the industry. "The co-founders at Harmonic Discovery have exceptional and complementary expertise across machine learning, medicinal chemistry and biotechnology business development to address the untapped potential of kinase drugs. We're thrilled to have Joel and the team at Innovation Endeavors on board to help us embrace our vision for the future of therapeutics," said Rayees Rahman, PhD, Harmonic Discovery's CEO and Co-Founder. We passionately believe that our unified approach to kinase drug discovery will be the first step in unlocking completely new ways to treat diseases. "There is an enormous opportunity to create safer and more effective drugs. By spanning multiple disciplines, including systems biology, cheminformatics, medicinal chemistry, and machine learning, the company believes it can develop novel therapies across diseases such as cancer and autoimmune disorders. The company's models learn from the topology of atoms and bonds that make up a kinase drug, to the three-dimensional ins and outs of kinase structure, all the way up to the dynamic cellular environments of disease driven by kinases. Harmonic Discovery's fully integrated kinase drug discovery platform aims to challenge this paradigm.Ĭo-founders Rayees Rahman, PhD, Jason Lee, MD, and Marcel Patek, PhD are building a machine learning-first infrastructure that integrates several aspects of kinase drug discovery. Yet, the pharmaceutical industry has historically focused on finding "magic bullets", or drugs optimized to engage specific single targets. Many drugs exert their effect through multiple modes of action which is a well-established phenomenon known as polypharmacology.
Joel Dudley, PhD, Partner at Innovation Endeavors, joins as a new Board Member. The round was led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital and select angel investors.
8, 2022 /PRNewswire/ - Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, announces its launch today with $8 million in seed funding. Joel Dudley as New Board Member, Company to Advance Development of Preclinical Drug Candidates in Oncology With Round Led by Innovation Endeavors & Dr.
0 kommentar(er)
